***Background.*** In Portugal, in May 2013 a VRSA strain (MRSA with vancomycin MIC = 1024 mg/l) was isolated from pus of a toe amputation wound of a 74 year-old female patient with chronic renal failure requiring haemodialysis, diabetes mellitus and peripheral vascular disease. The patient was under treatment with vancomycin for a methicillin-resistant *Staphylococcus aureus* (MRSA) local infection. Vancomycin-resistant *Enterococcus faecalis* (VRE) and *Pseudomonas aeruginosa* were also isolated from the wound.

***Methods.*** Antibiotic therapy with daptomycin, rifampicin and amikacin was administered for 6 weeks. Control precautions were reinforced. The strain was characterized and an epidemiological survey to monitor its possible dissemination was carried out. All isolates were characterized by multilocus sequence typing (MLST), *spa* typing, and pulsed-field gel electrophoresis (PFGE) profiling, and the structure of the *SCCmec* element of all MRSA isolates was determined.

***Results.*** The VRSA strain was no longer found in the wound after 3 weeks, and the VRE strain after 5 weeks. Nasal swabs from 53 close contacts (2 household members (HHM), 47 healthcare workers (HCW), 4 patients) did not reveal VRSA. Methicillin susceptible *Staphylococcus aureus* (MSSA) were recovered from 14 HCW, and 5 MRSA isolates were recovered from 3 HCW, 1 HHM and 1 patient. *S. aureus* isolates presented high genetic diversity, most of them belonging to clones previously identified in Portugal.

In countries with increase in CC5-associated clones and high prevalence of MRSA and VRE, such as Portugal, VRSA may arise more frequently in the near future.

***Conclusion.*** The VRSA strain harboured *vanA*, was ST105-II and belonged to CC5, as in 12 of the 13 cases detected in the USA. *vanA*-positive VRE may have been the donor of the *vanA* into a MRSA during co-infection and therapy with vancomycin. Transmission of the strain to contacts was not detected.
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